FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

PARIS and TARRYTOWN, N.Y., April 30, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news